Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: Double-blind study

https://doi.org/10.1016/0002-9343(87)90015-5Get rights and content

Abstract

To determine if long-term methotrexate-induced improvement of rheumatoid arthritis is sustained after the drug is discontinued, 10 unselected patients with responses to weekly oral methotrexate given for at least 36 months (mean 40.1) were randomly assigned to receive methotrexate or identical-appearing placebo tablets for two months. After one month, all five patients receiving placebo had to have the study terminated due to a flare of their disease manifested by statistically significant deterioration in multiple clinical parameters. It is concluded that patients receiving long-term methotrexate must continue the drug to maintain clinical benefits.

References (17)

  • RT Hoffmeister

    Methotrexate therapy in rheumatoid arthritis: 15 years experience

    Am J Med

    (1983)
  • A Weinstein et al.

    Low-dose pulse methotrexate treatment of rheumatoid arthritis

    Am J Med

    (1985)
  • ME Weinblatt et al.

    Efficacy of low-dose methotrexate in rheumatoid arthritis

    N Engl J Med

    (1985)
  • HJ Williams et al.

    Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial

    Arthritis Rheum

    (1985)
  • PA Andersen et al.

    Weekly pulse methotrexate in rheumatoid arthritis

    Ann Intern Med

    (1985)
  • JM Kremer et al.

    The safety and efficacy of methotrexate in the long-term therapy of rheumatoid arthritis

    Arthritis Rheum

    (1986)
  • G Weinstein et al.

    Psoriasis-liver-methotrexate interactions

  • A Nyfors

    Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics

    Acta Pathol Microbiol Scand

    (1977)
There are more references available in the full text version of this article.

Cited by (89)

  • Specific in vitro binding of a new <sup>99m</sup>Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils

    2015, International Journal of Pharmaceutics
    Citation Excerpt :

    The immunostimulating activity of [Re]ProTα-D1 was assessed in comparison with intact ProTα, the synthetic fragments ProTα[100-109], ProTα[100-105], ProTα[1-14],Tα1, ProTα[51-89] and ProTα[50-89]N50 W, the [Re]complex of a derivative encompassing the N-terminal fragment [1-14] of ProTα/Tα1 previously developed by our group ([Re]ProTα-D2), the positive-control peptide fMLP (Wittmann et al., 2002), the negative-control peptide NCP1a, and the negative-control [Re]complex, [Re]NCP1b. Two in vitro bioassays measuring superoxide anion production i.e., the nitroblue tetrazolium (NBT) reduction assay (Kremer et al., 1987) and reactive oxygen species (ROS) by flow cytometry (FC) using CM-H2DCFDA (Saito et al., 2013) were performed. Moreover, the zymosan particle incorporation assay was used to evaluate phagocytosis (Carvalho et al., 2000) in the presence of some of the compounds.

  • Methotrexate

    2015, Rheumatology: Sixth Edition
  • Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis

    2014, Joint Bone Spine
    Citation Excerpt :

    Again, dosage reduction seems preferable over the abrupt discontinuation of methotrexate or any other synthetic DMARD. Abrupt discontinuation is associated with a high relapse rate of about 70%, i.e., 2-fold that seen with continued treatment [113–115], and the reintroduction of the synthetic DMARD only inconsistently restores the previous status [116]. It would seem important to define a sustained remission using a strict composite criterion including the absence of synovitis, systemic inflammation, and structural disease progression [38,108–110].

  • Rheumatoid Arthritis

    2010, Current Clinical Medicine: Expert Consult Premium Edition - Enhanced Online Features and Print
View all citing articles on Scopus

This work was supported in part by National Institute of Health Grant 5M01-RR-00749-13 and a grant from Lederle Laboratories.

View full text